The chairman of Cambridge Therapeutics, John Klein is a pharmaceutical industry executive whose newest venture is the Alpine, NJ, based Bilogix. Focused on boosting operational effectiveness, Cambridge Therapeutics head John Klein has developed Bilogix’s next generation enterprise performance management (EPM) platform.
While there are various strategic approaches to EPM, one common approach involves utilizing an analytical framework while working to provide predictive capabilities. Through intuitive scorecards and dashboards, executives are able to view a variety of metrics across several business units that are arranged at various hierarchical levels.
Adhering to rigorous six sigma processes, EPM applications effectively contextualize operational strategy through key performance indicators that quantify results in terms of attaining targets. This approach allows organizational processes to be aligned across functions, with resources actively deployed in areas that will bring about sought after change and transformation.
Within an integrated EPM framework, steps taken to improve the corporate process are disseminated via financial consolidation and management reporting.